LGNZZ
What one share of Ligand Pharmaceuticals Incorporated holds
Pharmaceutical Preparations
We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.
Ligand Pharmaceuticals Incorporated’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $13.55 |
|---|---|
| Profit | $9.20 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $6.13 |
| Cash and investments | $50.54 |
| Debt | $56.56 |
| Book value | $48.57 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $5.23 | −$0.08 | $0.09 | $2.83 | — | $16.32 |
| 2017 | $6.01 | $0.53 | $0.09 | $3.68 | — | $18.90 |
| 2018 | $10.45 | $5.96 | $0.04 | $8.03 | — | $27.01 |
| 2019 | $6.09 | $31.85 | $0.13 | −$1.61 | — | $45.61 |
| 2020 | $9.72 | −$0.18 | $0.27 | $2.98 | — | $44.12 |
| 2021 | $14.01 | $3.31 | $0.51 | $4.06 | — | $48.97 |
| 2022 | $11.63 | −$1.98 | $1.06 | $7.11 | — | $35.25 |
| 2023 | $7.40 | $2.94 | $0.20 | $2.59 | — | $39.92 |
| 2024 | $9.14 | −$0.22 | $0.10 | $5.21 | — | $43.46 |
| 2025 | $13.21 | $6.13 | $0.02 | $2.41 | — | $51.44 |